Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:brand |
gptkb:Tyvaso
|
| gptkbp:clinical_trial |
Phase 3
|
| gptkbp:contraindication |
hypersensitivity to treprostinil
|
| gptkbp:dosage_form |
inhalation solution
|
| gptkbp:effective_date |
gptkb:2009
FDA approved |
| https://www.w3.org/2000/01/rdf-schema#label |
Tyvaso
|
| gptkbp:ingredients |
treprostinil
|
| gptkbp:invention |
patented
|
| gptkbp:is_used_for |
pulmonary arterial hypertension
|
| gptkbp:manager |
inhalation
|
| gptkbp:manufacturer |
gptkb:United_Therapeutics_Corporation
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:packaging |
multi-dose inhaler
|
| gptkbp:side_effect |
dizziness
headache nausea cough vomiting chest pain diarrhea shortness of breath jaw pain flushing |
| gptkbp:social_structure |
C20 H30 O5
|
| gptkbp:storage |
refrigerated
|
| gptkbp:bfsParent |
gptkb:Treprostinil
gptkb:United_Therapeutics_Corporation |
| gptkbp:bfsLayer |
6
|